Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Ulacamten · CK-4021586

Small molecule · developed by Cytokinetics

Phase 2 Most advanced trial

CYTK Developer

2 Registered trials

What is Ulacamten?

Ulacamten is an investigational small-molecule drug studied in Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF), Healthy Participants.

At a glance

Also known as: CK-4021586
Drug type: Small molecule
Therapy area: Cardiovascular
Developer: Cytokinetics (CYTK)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: X325G97HZJ

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06793371	Phase 2	Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)	Recruiting	CYTK
NCT05877053	Phase 1	Healthy Participants	Completed	CYTK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Participants

More from Cytokinetics

Aficamten FDA approved AMG 423 Phase 1 CK-3828136 Phase 1 Omecamtiv Mecarbil Phase 3 Reldesemtiv Phase 3 SB-743921 Phase 1/2 Tirasemtiv Phase 3

Sources

ClinicalTrials.gov NCT06793371

Updated Oct 3, 2026. Something wrong or missing? Report it on the CYTK page.

Follow CYTK, the company behind Ulacamten

See CYTK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CYTK catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z